alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM THE UNAUDITED FINANCIAL STATEMENTS FOR THE PERIOD ENDED
MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE
TO SUCH FINANCIAL STATEMENTS.
</LEGEND>

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                          DEC-31-2000
<PERIOD-START>                             JAN-01-2000
<PERIOD-END>                               MAR-31-2000
<CASH>                                              18
<SECURITIES>                                         0
<RECEIVABLES>                                    2,300
<ALLOWANCES>                                         0
<INVENTORY>                                          0
<CURRENT-ASSETS>                                 7,000
<PP&E>                                          23,036
<DEPRECIATION>                                   6,373
<TOTAL-ASSETS>                               3,882,666
<CURRENT-LIABILITIES>                           86,095
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                    750,000
<COMMON>                                         5,758
<OTHER-SE>                                   2,004,133
<TOTAL-LIABILITY-AND-EQUITY>                 3,882,666
<SALES>                                              0
<TOTAL-REVENUES>                                     0
<CGS>                                                0
<TOTAL-COSTS>                                   25,569
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                (25,569)
<INCOME-TAX>                                         0
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                   (25,569)
<EPS-BASIC>                                        0
<EPS-DILUTED>                                        0



</TABLE>
EXECUTIVE OFFICE OF THE PRESIDENT

OFFICE OF THE UNITED STATES TRADE REPRESENTATIVE

WASHINGTON, D.C. 20508

December 28, 2018

RE: Product Exclusion Request Number: USTR-2018-0025-2008

NTN Bearing Corporation of America:

I am pleased to notify you that the United States Trade Representative has determined to 

grant the above-referenced exclusion request submitted pursuant to the notice published at 83 FR 

32181 (‘July 11 notice’). The exclusion determination is set out in a formal notice which has 

been submitted to Office of the Federal Register for publication (‘the exclusion notice’). A prepublication version of the exclusion notice has been posted on the USTR website, at 

https://ustr.gov/sites/default/files/enforcement/301Investigations/12.21.18_Notice_of_Product_E

xclusions.pdf.

The scope of the exclusion is governed by the formal HTSUS language in the annex to 

the product exclusion notice, and not by the product descriptions set out in any particular request 

for exclusion. An exclusion in response to your request has been granted by excluding from the 

additional tariffs the 10-digit HTSUS subheading under which your request was filed. 

In accordance with the July 11 notice, the exclusion applies as of the July 6, 2018 

effective date of the tariff action, and will extend for one year after the exclusion notice is 

published in the Federal Register. As stated in the exclusion notice, U.S. Customs and Border 

Protection will issue additional instructions on entry guidance and implementation.

Sincerely,

Stephen P. Vaughn

General Counsel
EXHIBIT 32.2






CFO CERTIFICATION PURSUANT TO






SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002






(18 U.S.C. SECTION 1350)






In connection with Form 10-Q of POZEN Inc. (the “Company”) , as filed with the Securities and Exchange Commission (the “Report”), I, William L. Hodges, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:











1)
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and


2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
















Date:           October 29, 2009/s/  William L. HodgesWilliam L. HodgesChief Financial Officer

















































A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.
<TABLE> <S> <C>


                  <ARTICLE>                 5
<LEGEND>
                  This schedule contains summary financial information extracted
                  from MW Medical,  Inc. September 30, 1998 financial statements
                  and  is  qualified  in  its  entirety  by  reference  to  such
                  financial statements.
</LEGEND>

<CIK>                                        0001059577
<NAME>                                       MW Medical, Inc.

       

<S>                                          <C>
<PERIOD-TYPE>                                9-MOS
<FISCAL-YEAR-END>                            DEC-31-1998
<PERIOD-END>                                 SEP-30-1998
<CASH>                                                        1,242,172
<SECURITIES>                                                  0
<RECEIVABLES>                                                 445,278
<ALLOWANCES>                                                  0
<INVENTORY>                                                   0
<CURRENT-ASSETS>                                              1,809,467
<PP&E>                                                        249,427
<DEPRECIATION>                                                (162,748)
<TOTAL-ASSETS>                                                1,897,400
<CURRENT-LIABILITIES>                                         180,426
<BONDS>                                                       0
<PREFERRED-MANDATORY>                                         0
<PREFERRED>                                                   0
<COMMON>                                                      14,224
<OTHER-SE>                                                    1,702,750
<TOTAL-LIABILITY-AND-EQUITY>                                  1,897,400
<SALES>                                                       0
<TOTAL-REVENUES>                                              0
<CGS>                                                         0
<TOTAL-COSTS>                                                 0
<OTHER-EXPENSES>                                              753,650
<LOSS-PROVISION>                                              0
<INTEREST-EXPENSE>                                            0
<INCOME-PRETAX>                                               951,160
<INCOME-TAX>                                                  800
<INCOME-CONTINUING>                                           (753,650)
<DISCONTINUED>                                                (193,468)
<EXTRAORDINARY>                                               0
<CHANGES>                                                     0
<NET-INCOME>                                                  950,360
<EPS-PRIMARY>                                                 .07
<EPS-DILUTED>                                                 .07
        


</TABLE>
II 

117TH CONGRESS 

2D SESSION S. 4185 

To set forth limitations on exclusivity for orphan drugs. 

IN THE SENATE OF THE UNITED STATES 

MAY 11 (legislative day, MAY 10), 2022 

Ms. BALDWIN (for herself and Mr. CASSIDY) introduced the following bill; 

which was read twice and referred to the Committee on Health, Education, Labor, and Pensions 

A BILL 

To set forth limitations on exclusivity for orphan drugs. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Retaining Access and 

5 Restoring Exclusivity Act’’ or the ‘‘RARE Act’’. 

6 SEC. 2. LIMITATIONS ON EXCLUSIVE APPROVAL OR LICEN7 SURE OF ORPHAN DRUGS. 

8 (a) IN GENERAL.—Section 527 of the Federal Food, 

9 Drug, and Cosmetic Act (21 U.S.C. 360cc) is amended— 

10 (1) in subsection (a), in the matter following 

11 paragraph (2), by striking ‘‘same disease or condiVerDate Sep 11 2014 03:45 May 12, 2022 Jkt 029200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S4185.IS S4185

kjohnson on DSK79L0C42PROD with BILLS
2 

•S 4185 IS

1 tion’’ and inserting ‘‘same approved use or indica2 tion within such rare disease or condition’’; 

3 (2) in subsection (b)— 

4 (A) in the matter preceding paragraph (1), 

5 by striking ‘‘same rare disease or condition’’ 

6 and inserting ‘‘same approved use or indication 

7 for which such 7-year period applies to such al8 ready approved drug’’; and 

9 (B) in paragraph (1), by inserting ‘‘, relat10 ing to the approved use or indication,’’ after 

11 ‘‘the needs’’; 

12 (3) in subsection (c)(1), by striking ‘‘same rare 

13 disease or condition as the already approved drug’’ 

14 and inserting ‘‘same use or indication for which the 

15 already approved or licensed drug was approved or 

16 licensed’’; and 

17 (4) by adding at the end the following: 

18 ‘‘(f) APPROVED USE OR INDICATION DEFINED.—In 

19 this section, the term ‘approved use or indication’ means 

20 the use or indication approved under section 505 of this 

21 Act or licensed under section 351 of the Public Health 

22 Service Act for a drug designated under section 526 for 

23 a rare disease or condition.’’. 

24 (b) APPLICATION OF AMENDMENTS.—The amend25 ments made by subsection (a) shall apply with respect to 


kjohnson on DSK79L0C42PROD with BILLS
3 

•S 4185 IS

1 any drug designated under section 526 of the Federal 

2 Food, Drug, and Cosmetic Act (21 U.S.C. 360bb), regard3 less of the date on which the drug was so designated, and 

4 regardless of the date on which the drug was approved 

5 under section 505 of such Act (21 U.S.C. 355) or licensed 

6 under section 351 of the Public Health Service Act (42 

7 U.S.C. 262). 

Æ 


kjohnson on DSK79L0C42PROD with BILLS
#### The People of the State of New York, Respondent, v Daniel Barriento, Appellant.

[772 NYS2d 824]

Judgment, Supreme Court, Bronx County (Ira Globerman, J.), rendered April 4, 2000, convicting defendant, after a jury trial, of rape in the first degree (five counts), course of sexual conduct against a child in the first degree, rape in the second degree (three counts), sexual abuse in the first degree (five counts), and attempted sexual abuse in the first degree, and sentencing him to an aggregate term of 20 years, unanimously modified, on the law, to the extent of vacating the sentences on the convictions of rape in the second degree and substituting terms of 21/3 to 7 years on each of those convictions, and otherwise affirmed.

We conclude that under the circumstances presented, the report made by the younger of the two victims was too long after the events to qualify for admission under the “prompt outcry” exception to the hearsay rule. However, we find the error to be harmless (see *People v Leon,*209 AD2d 342 [1994], *lv denied*84 NY2d 1034 [1995]).

The court properly sustained the People’s objection to a question defendant asked on cross-examination of the victims’ mother, since the question, standing alone, was totally irrelevant to any issue in the case. It was not until a day after the witness had completed her testimony that defendant first explained that he had intended to open a line of inquiry suggesting a motive to fabricate. In any event, the court did not unduly restrict defendant’s cross-examination *(see People v Thomas,*46 NY2d 100, 105 [1978], *appeal dismissed*444 US 891 [1979]). To the extent that defendant is raising a constitutional claim, such claim is unpreserved and we decline to review it in the interest of justice. Were we to review this claim, we would reject it *(see Delaware v Van Arsdall,*475 US 673, 678-679 [1986]).

As the People correctly concede, the term of 31/3 to 10 years imposed for each conviction of rape in the second degree was not a lawful sentence for that class D felony (Penal Law § 70.00 [2] [d]). We see no reason for a remand for resentencing and *221instead replace the illegal sentence with a legal term of 21/3 to 7 years *(see People v White,*292 AD2d 239 [2002]), leaving the aggregate sentence unchanged. Concur—Andrias, J.P., Williams, Lerner, Friedman and Marlow, JJ.
MOTOR MODEL: RF330

VIEW 1 VIEW 2 VIEW 3
[Federal Register Volume 60, Number 42 (Friday, March 3, 1995)]
[Notices]
[Page 11975]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 95-5231]



-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health


National Center for Human Genome Research; Closed Meeting

    Pursuant to Section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2), notice is hereby given of the following 
meeting:

    Name of Committee: Genome Research Review Committee.
    Date: March 14, 1995.
    Time: 10 a.m. to adjournment.
    Place: Embassy Suites Hotel, Chevy Chase Pavilion, Washington, 
D.C.
    Contact Person: Ms. Linda Engel, Chief, Office of Scientific 
Review, National Center for Human Genome Research, National 
Institutes of Health, Building 38A, Room 604, Bethesda, Maryland 
20892, (301) 402-0838
    Purpose/Agenda: To review and evaluate grant applications and/or 
contract proposals.
    The meeting will be closed in accordance with the provisions set 
forth in secs. 552(c)(4) and 552(c)(6), Title 5, U.S.C. Applications 
and discussions could reveal confidential trade secrets or 
commercial property such as patentable material, and personal 
information concerning individuals associated with applications, the 
disclosure of which would constitute a clearly unwarranted invasion 
of personal privacy.

(Catalog of Federal Domestic Assistance Program No. 93.172, Human 
Genome Research)

    Date: February 17, 1995.
Susan K. Feldman,
Committee Management Officer, NIH.
[FR Doc. 95-5231 Filed 3-2-95; 8:45 am]
BILLING CODE 4140-01-M
EXHIBIT 31.2



I, Lewis J. Derbes, Jr., certify that:



1. I have reviewed this quarterly report on Form 10-Q of Conrad Industries, Inc.;



2. Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the
statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;



3. Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all
material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this quarterly report;



4. The registrants other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and
procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and have:



a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including
its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this quarterly report is being prepared;



b) [intentionally omitted]



c) evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the
effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and



d) disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most
recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and



5. The registrants other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over
financial reporting, to the registrants auditors and the audit committee of the registrants board of directors:



a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably
likely to adversely affect the registrants ability to record, process, summarize and report financial information; and



b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control
over financial reporting.



|Date: November 12, 2003.                                     
|-------------------------------------------------------------
|                                                             
|/s/ LEWIS J. DERBES, JR.                                     
|Lewis J. Derbes, Jr. Vice President & Chief Financial Officer



31
IN THE SUPREME COURT OF PENNSYLVANIA

IN RE:

 AMENDMENT OF RULES 219(a) 

AND 502(b) OF THE 

PENNSYLVANIA RULES OF 

DISCIPLINARY ENFORCEMENT 

AND RULE 1.15 OF THE RULES 

OF PROFESSIONAL CONDUCT

:

:

:

:

:

:

:

:

:

NO. 172

DISCIPLINARY RULES DOCKET

ORDER

PER CURIAM

AND NOW, this 7

th day of February, 2019, it is hereby ORDERED that Rules 

219(a) and 502(b) of the Pennsylvania Rules of Disciplinary Enforcement and Rule 1.15 

of the Rules of Professional Conduct are amended in the attached form. These 

amendments shall be effective for the 2019-20 annual attorney assessment and shall 

continue until further Order of this Court. 

Pursuant to Rule 103 of the Pennsylvania Rules of Judicial Administration, the 

immediate amendment of Rules 219(a) and 502(b) of the Pennsylvania Rules of 

Disciplinary Enforcement and Rule 1.15 of the Rules of Professional Conduct is required 

in the interest of efficient administration. 

This ORDER shall be processed in accordance with Rule 103(b) of the 

Pennsylvania Rules of Judicial Administration and shall be effective immediately. 

Additions to the rule are shown in bold and are underlined.

Deletions from the rule are shown in bold and in brackets.
<TABLE> <S> <C>


<ARTICLE>                     5
<MULTIPLIER>                                   1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                              DEC-31-1998
<PERIOD-START>                                 JUL-01-1998
<PERIOD-END>                                   SEP-30-1998
<CASH>                                         15,643
<SECURITIES>                                   0
<RECEIVABLES>                                  10,073
<ALLOWANCES>                                   0
<INVENTORY>                                    10,781
<CURRENT-ASSETS>                               37,397
<PP&E>                                         32,514
<DEPRECIATION>                                 (13,823)
<TOTAL-ASSETS>                                 57,932
<CURRENT-LIABILITIES>                          9,868
<BONDS>                                        2,761
<PREFERRED-MANDATORY>                          0
<PREFERRED>                                    0
<COMMON>                                       175
<OTHER-SE>                                     44,029
<TOTAL-LIABILITY-AND-EQUITY>                   57,932
<SALES>                                        47,158
<TOTAL-REVENUES>                               47,158
<CGS>                                          32,798
<TOTAL-COSTS>                                  32,798
<OTHER-EXPENSES>                               6,000
<LOSS-PROVISION>                               0
<INTEREST-EXPENSE>                             (379)
<INCOME-PRETAX>                                7,981
<INCOME-TAX>                                   2,921
<INCOME-CONTINUING>                            5,060
<DISCONTINUED>                                 0
<EXTRAORDINARY>                                0
<CHANGES>                                      0
<NET-INCOME>                                   5,060
<EPS-PRIMARY>                                  .74
<EPS-DILUTED>                                  .72
        


</TABLE>
U.S. flagAn official website of the United States government
                    Here's how you know **Official websites use .gov**
                            
                            A **.gov** website belongs to an official government organization in the United States.
 **Secure .gov websites use HTTPS**
                            
                            A **lock** (                            
                              A locked padlock                                                      
                            
                            ) or **https://** means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.


Menu Agricultural Research Service
						
                    U.S. DEPARTMENT OF AGRICULTURE
 Great Basin Rangelands Research: Reno, NV
 close



    Research

                    Research Projects
                                    Publications
                                    Collaborations
                                    News
                People

                    Staff Listing
                                    Careers


        


                    Newsletter
                        Volume 1
                                    Volume 2Search small
                    Search
            
            ARS Home
                                About ARS
                                Contact Us




ARS Home Pacific West Area Reno, Nevada Great Basin Rangelands Research Research





- ARS National Programs
- Search for a scientific manuscript
- Search for a research project
- ARS Software
- Programs and Projects
- Collaborations
- Subjects of Investigation
- Publications

Research Projects Subjects of Investigation at this LocationEach ARS research project has related subjects of investigation.  Listed below are the subjects of investigation currently conducted at this location.
Clicking on a subject of investigation will list the research projects within that  subject of investigation.Subjects of Investigation
                            Desert and semidesert shrub land and shinnery
                                Pinyon-juniper
                                Rangelands and grasslands, general
                                Watersheds
                                Weeds


Return to top


Connect with ARS Sign up


ARS Home
                            USDA.gov
                            Plain Writing
                            Policies & Links
                            Civil Rights Statements
                            FOIA
                            Accessibility Statement
                            Privacy Policy
                            Non-Discrimination Statement
                            Quality of Information
                            USA.gov
                            WhiteHouse.gov